Theravance Biopharma, Inc. Deferred Tax Liabilities, Prepaid Expenses
Theravance Biopharma, Inc. (TBPH) had Deferred Tax Liabilities, Prepaid Expenses of $221.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilitiesPrepaidExpenses · last filed 2026-03-23
- 2025-12-31: Deferred Tax Liabilities, Prepaid Expenses $221.00K.
- 2024-12-31: Deferred Tax Liabilities, Prepaid Expenses $268.00K.
- 2021-12-31: Deferred Tax Liabilities, Prepaid Expenses $255.00K; Deferred Tax Liabilities, Prepaid Expenses as first filed $254.00K.
- 2020-12-31: Deferred Tax Liabilities, Prepaid Expenses $341.00K.
| Period end | Deferred Tax Liabilities, Prepaid Expenses | Deferred Tax Liabilities, Prepaid Expenses as first filed |
|---|---|---|
| 2025-12-31 | $221.00K 10-K · filed 2026-03-23 | |
| 2024-12-31 | $268.00K 10-K · filed 2026-03-23 | |
| 2021-12-31 | $255.00K 10-K · filed 2023-03-01 | $254.00K 10-K · filed 2022-02-28 |
| 2020-12-31 | $341.00K 10-K · filed 2022-02-28 | |
| 2019-12-31 | $459.00K 10-K · filed 2021-02-26 | |
| 2018-12-31 | $208.00K 10-K · filed 2020-02-27 | |
| 2017-12-31 | $152.00K 10-K · filed 2019-02-28 | |
| 2016-12-31 | $361.00K 10-K · filed 2018-02-28 | |
| 2015-12-31 | $600.00K 10-K · filed 2017-03-01 | |
| 2014-12-31 | $384.00K 10-K · filed 2016-03-11 | -$384.00K 10-K · filed 2015-03-13 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |